Freenome Inc. (FRNM)
NASDAQ: FRNMHealth CareMedical SpecialitiesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
FRNM stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.04B
- EPS (TTM)
- -$1.28
- Dividend yield
- None
- 52-week range
- 9.28 – 17.50
- Day range
- 9.28 – 9.84
- Volume / Avg
- 621.42K / 833.65K
- Beta
- —
- Shares outstanding
- 111.50M
52-week range
FRNM stock today
Shares of Freenome (FRNM) finished lower on Nov 20 at $9.36, a drop of 5.69% or $0.565 per share, versus the S&P 500's 3.70% decline. Shares are 46.5% below their 52-week high of $17.50, set on Sep 21, 2026 and 0.9% above the 52-week low of $9.28, near the bottom of the past year's range. FRNM is down 28.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 12.9%.
Freenome has posted a net loss over the last twelve months (EPS of -$1.28), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Freenome
Company profileFreenome, Inc., a biotechnology company, develops blood-based screening tests to detect cancer in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer. It develops SimpleScreen CRC, a blood-based test, including a test for colorectal cancer screening, as well as tests for multi-cancer and multi-disease detection, such as lung, breast, cervical, liver, pancreatic, and esophageal cancers.
- Sector
- Health Care
- Industry
- Medical Specialities
- CEO
- Mr. Aaron Elliott Ph.D.
- Headquarters
- Brisbane, CA
- Employees
- 363
- Website
- freenome.com
Financial highlights
Full financialsNet income was $837,468.
| Fiscal year | FY 2025 |
|---|---|
| Revenue | — |
| Growth | — |
| Net income | $837.47K |
| EPS (diluted) | — |
Analyst forecast
ForecastConsensus (5 analysts)
strong_buy
Avg. price target
$18.00+92.31%
- Strong buy 0
- Buy 5
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 10, 2026
- EPS actual vs est.
- $0.01 vs —
FRNM news
All FRNM news- Freenome (FRNM) Q3 2026 Earnings Call TranscriptNasdaqFRNM, MOG.B
- Freenome to Participate in the Piper Sandler 38th Annual Healthcare ConferenceGlobeNewswire
- Freenome GAAP EPS of $0.58 beats by $0.49, revenue of $183.49M beats by $98.64MSeeking Alpha
- Freenome Reports Third Quarter 2026 Financial ResultsGlobeNewswire
- Cathie Wood Goes Bargain Hunting: 3 Stocks She Just BoughtNasdaqCRWV, FRNM, SCTX
- Freenome Expands Personalized Cancer Detection Portfolio, Launching SimpleScreen™ Lung Test With FDA-Approved SimpleScreen CRC OptionGlobeNewswire
- Freenome to Report Third Quarter 2026 Financial Results on November 10, 2026GlobeNewswire
- Freenome To Present Improved Precancerous Lesion Detection Data For CRC Blood TestNasdaqABT, FRNM
Freenome peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CSTLCastle Biosciences Inc. | 32.86 | -1.63% | $1.01B | vs FRNM |
| ALHCAlignment Healthcare Inc. | 6.37 | -2.00% | $1.33B | vs FRNM |
| LMRILumexa Imaging Holdings Inc. | 14.26 | +1.42% | $1.37B | vs FRNM |
| FLGTFulgent Genetics Inc. | 24.12 | -2.66% | $673.89M | vs FRNM |
| TRUPTrupanion Inc. | 35.56 | -0.86% | $1.54B | vs FRNM |
| PSNLPersonalis Inc. | 14.27 | -3.06% | $1.55B | vs FRNM |
| YDESYD Bio Limited | 4.83 | +5.92% | $342.12M | vs FRNM |
| FTREFortrea Holdings Inc. | 18.55 | -7.94% | $1.79B | vs FRNM |
Indexes, lists and sector
Freenome stock FAQ
What is Freenome's stock price today?
FRNM last traded at $9.36 as of Nov 20, 4:00 PM EST, down 5.69% on the day. Prices are delayed at least 15 minutes.
Who is Freenome's CEO?
Mr. Aaron Elliott Ph.D. is the chief executive officer of Freenome Inc., which has about 363 employees.
What is the FRNM 52-week high?
The 52-week high for FRNM is $17.50 and the 52-week low is $9.28. The stock is currently 46.5% below its high.